AgustÃ-n Albillos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1979194/publications.pdf

Version: 2024-02-01

145 papers 11,375 citations

53 h-index 36203 101 g-index

158 all docs

158 docs citations

158 times ranked 9837 citing authors

#	Article	IF	CITATIONS
1	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». GastroenterologÃa Y HepatologÃa, 2023, 46, 236-247.	0.2	2
2	Cirrhosis-associated immune dysfunction. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 112-134.	8.2	139
3	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	2.4	42
4	Congestive Cardiac Hepatopathy. , 2022, , 189-213.		O
5	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	2.0	7
6	Noninvasive Prediction of Outcomes in Autoimmune Hepatitis–Related Cirrhosis. Hepatology Communications, 2022, 6, 1392-1402.	2.0	5
7	Self-expandable metal stent fixation with a temporary Overstitch Apollo� suture as a rescue therapy for a reluctant tuberculous esophageal-mediastinal fistula. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	1
8	Nonâ€selective betaâ€blockers in patients with ascites: TheÂcomplex interplay among the liver, kidney and heart. Liver International, 2022, 42, 749-761.	1.9	18
9	Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleedingâ€. Journal of Hepatology, 2022, 76, 752-753.	1.8	O
10	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologAa Y HepatologAa, 2022, 45, 724-734.	0.2	3
11	Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies. Current Oncology, 2022, 29, 2442-2453.	0.9	6
12	Prognostic role of ISR-4 in the survival of patients with pancreatic cancer Histology and Histopathology, 2022, , 18432.	0.5	4
13	Over the scope clip (OTSC) as rescue treatment for gastrointestinal bleeding secondary to peptic ulcer disease. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	О
14	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. Alimentary Pharmacology and Therapeutics, 2022, 56, 131-143.	1.9	9
15	An Updated View of the Importance of Vesicular Trafficking and Transport and Their Role in Immune-Mediated Diseases: Potential Therapeutic Interventions. Membranes, 2022, 12, 552.	1.4	8
16	Postsurgical bile duct disruption: Digital single-operator cholangioscopy-assisted recanalization. Endoscopy, 2021, 53, 764-765.	1.0	0
17	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acuteâ€onâ€chronic liver failure and acute decompensation. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 240-248.	1.4	11
18	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	0.6	97

#	Article	IF	CITATIONS
19	Hepatocellular carcinoma after Fontan surgery: A systematic review. Hepatology Research, 2021, 51, 116-134.	1.8	30
20	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1627-1633.	1.4	19
21	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
22	Reply to: "Open or closed window: That is the question― Journal of Hepatology, 2021, 74, 486-487.	1.8	0
23	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. Hepatology Communications, 2021, 5, 309-322.	2.0	13
24	Systemic Inflammation and the Breakdown of Intestinal Homeostasis Are Key Events in Chronic Spinal Cord Injury Patients. International Journal of Molecular Sciences, 2021, 22, 744.	1.8	18
25	Mild ast elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort. Revista Espanola De Enfermedades Digestivas, 2021, 113, 780-786.	0.1	2
26	Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder. Journal of Personalized Medicine, 2021, 11, 220.	1.1	32
27	The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Frontiers in Immunology, 2021, 12, 660179.	2.2	56
28	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e587-e593.	0.8	1
29	The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. Journal of Hepatology, 2021, 75, S82-S100.	1.8	37
30	"Positron emission tomography for the diagnosis of tipsitis― Digestive and Liver Disease, 2021, 53, 1675-1677.	0.4	0
31	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	1.8	28
32	Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management. Seminars in Liver Disease, 2021, 41, 538-550.	1.8	5
33	A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Reports, 2021, 3, 100291.	2.6	23
34	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology, 2021, 75, 589-599.	1.8	36
35	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	2.6	3
36	Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review). Oncology Letters, 2021, 22, 809.	0.8	7

#	Article	IF	Citations
37	O09â€A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5
38	A new single-use disposable duodenoscope (EXALTi; ½ Model D) for the treatment of an anastomotic biliary stenosis in a liver transplant patient. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.1	1
39	Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy International Open, 2021, 09, E1740-E1751.	0.9	15
40	The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of Hepatology, 2020, 72, 558-577.	1.8	935
41	Efficacy of Albumin Treatment for Patients with CirrhosisÂandÂlnfections Unrelated to Spontaneous BacterialÂPeritonitis. Clinical Gastroenterology and Hepatology, 2020, 18, 963-973.e14.	2.4	77
42	Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2020, 18, 216-225.e5.	2.4	104
43	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	2.4	74
44	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. Journal of Hepatology, 2020, 72, 702-710.	1.8	45
45	Fontan proteinâ€losing enteropathy is associated with advanced liver disease and a proinflammatory intestinal and systemic state. Liver International, 2020, 40, 638-645.	1.9	22
46	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	1.8	107
47	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	1.9	39
48	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	1.8	223
49	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
50	Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists. Clinical Gastroenterology and Hepatology, 2020, , .	2.4	8
51	Letter: improve survival! Place early preâ€emptive TIPSS in highâ€risk variceal bleeders. Alimentary Pharmacology and Therapeutics, 2020, 52, 927-928.	1.9	5
52	Reply to: "Beta-blockers in refractory ascites – is it truly the end of the road?― Journal of Hepatology, 2020, 73, 1291-1292.	1.8	1
53	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. Clinical Infectious Diseases, 2020, 71, 2726-2729.	2.9	23
54	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. Journal of Infectious Diseases, 2020, 222, 726-733.	1.9	43

#	Article	IF	CITATIONS
55	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424.	1.8	104
56	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology, 2020, 73, 17-25.	1.8	59
57	Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study. Pancreatology, 2020, 20, 331-337.	0.5	11
58	Lumen-apposing metal stents versus biliary fully-covered metal stents for EUS-guided drainage of pancreatic fluid collections: a case control study. Endoscopy International Open, 2020, 08, E6-E12.	0.9	9
59	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	1.8	97
60	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	1.8	112
61	Blunted Expansion of Regulatory T Lymphocytes Is Associated With Increased Bacterial Translocation in Patients With Major Depressive Disorder. Frontiers in Psychiatry, 2020, 11, 591962.	1.3	25
62	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. Journal of Hepatology, 2020, 73, 1404-1414.	1.8	58
63	Management of pancreatic collections: an update. Revista Espanola De Enfermedades Digestivas, 2020, 112, 483-490.	0.1	4
64	OUTCOMES OF DRUG-INDUCED ACUTE PANCREATITIS: A TEN-YEAR EXPERIENCE OF AN ACADEMIC CENTER. Revista Espanola De Enfermedades Digestivas, 2020, 113, 276-279.	0.1	4
65	Preemptive‶IPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	3.6	144
66	Sepsis in Patients With Cirrhosis Awaiting Liver Transplantation: New Trends and Management. Liver Transplantation, 2019, 25, 1700-1709.	1.3	6
67	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. Journal of Hepatology, 2019, 71, 942-950.	1.8	61
68	FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. Journal of Hepatology, 2019, 71, 1126-1140.	1.8	153
69	Biliary sphincterotomy reduces the risk of acute gallstone pancreatitis recurrence in non-candidates for cholecystectomy. Digestive and Liver Disease, 2019, 51, 1567-1573.	0.4	12
70	Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis. Gastrointestinal Endoscopy, 2019, 90, 581-590.e6.	0.5	35
71	Hepatic angiosarcoma in a patient with liver cirrhosis. GastroenterologÃa Y HepatologÃa, 2019, 42, 304-305.	0.2	2
72	Genetic and flow cytometry analysis of seronegative celiac disease: a cohort study. Scandinavian Journal of Gastroenterology, 2019, 54, 563-570.	0.6	10

#	Article	IF	CITATIONS
73	Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango. Frontiers in Immunology, 2019, 10, 973.	2.2	60
74	Characteristics and consequences of missed gastric cancer: A multicentric cohort study. Digestive and Liver Disease, 2019, 51, 894-900.	0.4	21
75	\hat{l}^2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2019, 393, 1597-1608.	6.3	375
76	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. Hepatology, 2019, 70, 911-924.	3.6	11
77	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	2.2	134
78	Reply. Hepatology, 2019, 69, 2306-2307.	3.6	0
79	Abnormal Distribution and Function of Circulating Monocytes and Enhanced Bacterial Translocation in Major Depressive Disorder. Frontiers in Psychiatry, 2019, 10, 812.	1.3	53
80	Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study. United European Gastroenterology Journal, 2019, 7, 189-198.	1.6	46
81	Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis. Hepatology, 2019, 70, 925-938.	3.6	70
82	$P\tilde{A}^3$ lipo de Nakamura: un hallazgo endosc \tilde{A}^3 pico infrecuente. Gastroenterolog \tilde{A} a Y Hepatolog \tilde{A} a, 2019, 42, 34-35.	0.2	2
83	Trasplante de precursores hematopoyéticos en enfermedad de Crohn refractaria: experiencia en nuestro centro. GastroenterologÃa Y HepatologÃa, 2019, 42, 16-22.	0.2	3
84	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	1.8	225
85	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	3.6	80
86	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del HÃgado (AEEH). GastroenterologÃa Y HepatologÃa, 2019, 42, 579-592.	0.2	25
87	Enfermedad hepática por alcohol. GuÃas de práctica clÃnica. Documento de consenso auspiciado por la AEEH. GastroenterologÃa Y HepatologÃa, 2019, 42, 657-676.	0.2	12
88	Clinical validation of Endofaster $1/2$ for a rapid diagnosis of Helicobacter pylori infection. Revista Espanola De Enfermedades Digestivas, 2019, 112, 23-26.	0.1	6
89	A multicentric Spanish study on the characteristics and survival of gastric adenocarcinoma under the age of 60. GastroenterologÃa Y HepatologÃa, 2019, 42, 595-603.	0.2	4
90	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. Therapeutic Advances in Gastroenterology, 2019, 12, 1756284819879565.	1.4	6

#	Article	IF	Citations
91	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). GuÃa de práctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.2	71
92	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	0.6	162
93	Fontan-associated Liver Disease. Revista Espanola De Cardiologia (English Ed), 2018, 71, 192-202.	0.4	12
94	Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. Digestive and Liver Disease, 2018, 50, 1345-1350.	0.4	4
95	Incidence, predictive factors and impacts of acute kidney injury in cirrhotic patients hospitalized for cellulitis. Liver International, 2018, 38, 285-294.	1.9	7
96	Fontan-Associated Liver Disease: A Review. Annals of Hepatology, 2018, 17, 192-204.	0.6	65
97	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Revista Espanola De Enfermedades Digestivas, 2018, 110, 641-649.	0.1	3
98	Experiencia en pr \tilde{A}_i ctica cl \tilde{A} nica de optimizaci \tilde{A}^3 n de tiopurinas mediante determinaci \tilde{A}^3 n de sus metabolitos en la enfermedad inflamatoria intestinal. Gastroenterolog \tilde{A} a Y Hepatolog \tilde{A} a, 2018, 41, 629-635.	0.2	7
99	Risk stratification and treatment of primary biliary cholangitis. Revista Espanola De Enfermedades Digestivas, 2018, 111, 63-70.	0.1	1
100	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for endâ€stage liver disease: Analysis of data from the Hepa registry. Hepatology, 2017, 65, 1810-1822.	3.6	78
101	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of Hepatology, 2017, 66, 1138-1148.	1.8	159
102	Targeting the gut-liver axis in liver disease. Journal of Hepatology, 2017, 67, 1084-1103.	1.8	311
103	Sepsis in alcohol-related liver disease. Journal of Hepatology, 2017, 67, 1031-1050.	1.8	93
104	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient metaâ€analysis. Hepatology, 2017, 66, 1219-1231.	3.6	80
105	Do patients with iron deficiency without anemia benefit from an endoscopic examination?. Journal of Digestive Diseases, 2017, 18, 416-424.	0.7	6
106	Acute variceal bleeding in patients on primary prophylaxis with nonselective betaâ€blockers: A poor prognosis factor?. Hepatology, 2017, 65, 1774-1774.	3.6	0
107	Effects of All-Oral Anti-Viral Therapy on HVPG and SystemicÂHemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1.	0.6	210
108	Enfermedades vasculares del hÃgado. GuÃas ClÃnicas de la Sociedad Catalana de DigestologÃa y de la Asociación Española para el Estudio del HÃgado. GastroenterologÃa Y HepatologÃa, 2017, 40, 538-580.	0.2	20

#	Article	IF	CITATIONS
109	The endoscopic ultrasound-assisted Rendez-Vous technique for treatment of recurrent pancreatitis due to pancreas divisum and ansa pancreatica. Revista Espanola De Enfermedades Digestivas, 2017, 109, 798-800.	0.1	6
110	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology, 2016, 64, 224-231.	3.6	69
111	Continued controversy over the safety of betaâ€blockers in decompensated cirrhosis. Hepatology, 2016, 63, 1726-1729.	3.6	3
112	Development of hyperdynamic circulation and response to βâ€blockers in compensated cirrhosis with portal hypertension. Hepatology, 2016, 63, 197-206.	3.6	143
113	Reply. Gastroenterology, 2016, 151, 761-762.	0.6	0
114	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. Hepatology, 2016, 64, 1249-1264.	3.6	550
115	Prognostic value of bacterial infection in acute and chronic liver failure. Liver International, 2016, 36, 1090-1092.	1.9	4
116	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	0.6	232
117	Evaluation of the short- and long-term effectiveness and safety of fully covered self-expandable metal stents for drainage of pancreatic fluid collections: results of a Spanish nationwide registry. Gastrointestinal Endoscopy, 2016, 84, 450-457.e2.	0.5	81
118	Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. Journal of Hepatology, 2016, 64, 1049-1057.	1.8	139
119	Impact of anticoagulation on upperâ€gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology, 2015, 62, 575-583.	3.6	105
120	Nonâ€selective betaâ€blockers may reduce risk of hepatocellular carcinoma: a metaâ€analysis of randomized trials. Liver International, 2015, 35, 2009-2016.	1.9	65
121	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. American Journal of Gastroenterology, 2015, 110, 985-992.	0.2	25
122	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1846-1853.e1.	2.4	60
123	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. Journal of Hepatology, 2014, 60, 1310-1324.	1.8	685
124	Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology, 2014, 61, 1385-1396.	1.8	870
125	Secondary Prophylaxis for Esophageal Variceal Bleeding. Clinics in Liver Disease, 2014, 18, 359-370.	1.0	20
126	Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis. Journal of Hepatology, 2013, 59, 723-730.	1.8	51

#	Article	IF	Citations
127	Systemic inflammation in absence of gut bacterial translocation in C57BL/6 mice with cirrhosis. Gut, 2013, 62, 330-331.	6.1	4
128	The window hypothesis: haemodynamic and non-haemodynamic effects of \hat{l}^2 -blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1. Gut, 2012, 61, 967-969.	6.1	180
129	Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology, 2012, 56, 1861-1869.	3.6	56
130	Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology, 2010, 52, 2086-2095.	3.6	41
131	The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis. Gut, 2010, 59, 943-952.	6.1	9
132	Role of Endoscopy in Primary Prophylaxis for Esophageal Variceal Bleeding. Clinics in Liver Disease, 2010, 14, 231-250.	1.0	5
133	Meta-analysis: Combination Endoscopic and Drug Therapy to Prevent Variceal Rebleeding in Cirrhosis. Annals of Internal Medicine, 2008, 149, 109.	2.0	169
134	Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis. American Journal of Gastroenterology, 2007, 102, 1116-1126.	0.2	137
135	The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut, 2007, 56, 259-264.	6.1	24
136	Preventing First Variceal Hemorrhage in Cirrhosis. Journal of Clinical Gastroenterology, 2007, 41, S305-S311.	1.1	28
137	Mesenteric Th1 polarization and monocyte TNF- \hat{l}_{\pm} production: First steps to systemic inflammation in rats with cirrhosis. Hepatology, 2005, 42, 411-419.	3.6	62
138	A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. Journal of Hepatology, 2005, 43, 990-996.	1.8	151
139	Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. Journal of Hepatology, 2004, 40, 624-631.	1.8	128
140	Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet, The, 2004, 363, 1608-1610.	6.3	93
141	Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology, 2003, 37, 208-217.	3.6	381
142	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 2002, 36, 1367-1373.	3.6	121
143	Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology, 2000, 31, 43-48.	3.6	228
144	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. Hepatology, 2000, 32, 471-476.	3.6	196

AGUSTÃN ALBILLOS

#	Article	lF	CITATIONS
145	Increased spontaneous and lymphokine-conditioned IgA and IgG synthesis by B cells from alcoholic cirrhotic patients. Hepatology, 1992, 16, 664-670.	3.6	38